FINWIRES · TerminalLIVE
FINWIRES

$GRAL

12 stories mentioning GRALUpdated just now

Every FINWIRES story that references GRAL, newest first.

What are analysts saying about GRAL?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on GRAL?

Wire

GRAIL Risk-Reward Attractive Ahead of FDA Advisory Committee, UBS Says

GRAIL (GRAL) has an attractive risk-reward profile ahead of the FDA's Sept. 23 advisory committee meeting on its Galleri multi-cancer detection assay, UBS said in a note.UBS said 225 of 227 public comments submitted to the FDA as of Sept. 15 supported approval, while eight called for stricter labeling, clearer cancer-specific performance disclosures and post-market evidence.The bank expects the FDA briefing documents to provide more clarity on the panel's focus. UBS said the safety profile from the PATHFINDER 2 study provides a strong foundation, while the NHS-Galleri trial's failure to meet its primary endpoint is a notable risk.UBS expects FDA approval next year and said a failure to gain approval could leave the stock trading around $40 to $50 per share, while approval could result in a $150 to $170 per share valuation.UBS reiterated a buy rating and $105 price target.Price: $80.52, Change: $+0.57, Percent Change: +0.71%

$GRAL
Wire

Grail's Galleri Test Has Large Market Potential Amid Adoption Curve Concerns, RBC Capital Markets Says

Grail's (GRAL) Galleri multi-cancer early detection test could unlock a "substantial" market opportunity, but adoption and reimbursement hurdles could limit near-term sales, RBC Capital Markets said in a note Thursday.The investment firm said Galleri could gain US Food and Drug Administration approval in late 2026 or early 2027, which would provide a "compelling" catalyst for the stock.Even with potential approval, RBC expects slower sales ramp than Wall Street and sees cash burn increasing year over year in 2027.The firm forecast $430 million in sales in 2030, compared with a consensus estimate of about $512 million, citing "limited" demand from patients paying out-of-pocket and a lack of broad insurance coverage.RBC Capital Markets initiated coverage of Grail with a sector perform rating and a price target of $84.Grail's shares were 4.3% higher in Thursday trading.Price: $78.32, Change: $+3.21, Percent Change: +4.27%

$GRAL
Research

RBC Initiates GRAIL at Sector Perform With $84 Price Target

GRAIL (GRAL) has an average rating of overweight and mean price target of $77.70, according to analysts polled by FactSet.

$GRAL
Wire

GRAIL's Galleri Blood Test to Be Evaluated by US FDA Advisory Panel

GRAIL (GRAL) said Friday that an advisory panel of the US Food and Drug Administration will convene on Sept. 23 to evaluate the premarket approval application for its Galleri multi-cancer early detection blood test.The firm submitted the marketing application Jan. 29, incorporating trial results from 25,490 participants in its PATHFINDER 2 study along with over 70,000 subjects from its NHS-Galleri trial, the company said.Shares of the company were up about 8.9% in Friday trading.Price: $69.03, Change: $+5.63, Percent Change: +8.88%

$GRAL
Research

Goldman Sachs Initiates Coverage on GRAIL With Neutral Rating, $60 Price Target

GRAIL Inc (GRAL) has an average rating of overweight and mean price target of $66, according to analysts polled by FactSet.

$GRAL
Sectors

Sector Update: Healthcare Stocks Fall Late Afternoon

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.1%.The iShares Biotechnology ETF (IBB) shed 1.4%.In corporate news, Cardiff Oncology (CRDF) shares tumbled past 21% after HC Wainwright downgraded the stock to neutral from buy, and TD Cowen to hold from buy.GRAIL (GRAL) stock dropped 9.7% after the company said the NHS-Galleri trial of its Galleri multi-cancer early detection test missed its primary endpoint.Jasper Therapeutics (JSPR) shares tumbled 32% after the firm said its board has launched a review of strategic alternatives, including a sale of assets, a sale of the company, merger, or an orderly wind-down of operations.Edgewise Therapeutics (EWTX) has agreed to sell its muscular dystrophy business to Servier for up to $2.65 billion, Servier said Monday. Edgewise shares jumped past 13%.

$CRDF$EWTX$GRAL$JSPR
Sectors

Sector Update: Healthcare Stocks Fall in Afternoon Trading

Healthcare stocks declined Monday afternoon, with the NYSE Healthcare Index falling 1.6% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.4%.The iShares Biotechnology ETF (IBB) shed 1.6%.In corporate news, GRAIL's (GRAL) stock dropped 14% after the company said the NHS-Galleri trial of its Galleri multi-cancer early detection test missed its primary endpoint.Jasper Therapeutics (JSPR) shares dropped 17% after it said Monday that its board has launched a review of strategic alternatives, including a potential sale of assets, licensing deals, collaborations, merger, business combination, sale of the company or an orderly wind-down of operations.Edgewise Therapeutics (EWTX) has agreed to sell its muscular dystrophy business to Servier for up to $2.65 billion, Servier said Monday. Edgewise shares jumped 13%.Humana (HUM) shares climbed 6.1% after the company said it plans to reaffirm its full-year adjusted earnings guidance of at least $9 per share during upcoming meetings.

$EWTX$GRAL$HUM$JSPR
Sectors

Sector Update: Healthcare Stocks Decline Premarket Monday

Healthcare stocks were declining premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.6% and the iShares Biotechnology ETF (IBB) 0.1% lower.Humana (HUM) shares were up more than 4% after the company said it plans to reaffirm its full-year adjusted earnings guidance of at least $9 per share during upcoming meetings.GRAIL's (GRAL) stock was down more than 17% after the company said the NHS-Galleri trial of its Galleri multi-cancer early detection test missed its primary endpoint.Biohaven (BHVN) shares were up more than 1% after the company said it has initiated first-in-human dosing of BHV-8100, an experimental oral, brain-penetrant PKM2 modulator being developed for neurological, retinal and inflammatory diseases.

$BHVN$GRAL$HUM$IBB$XLV
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as AI Optimism Overshadows Middle East Risks

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively traded Invesco QQQ Trust (QQQ) advanced 0.2% in Monday's premarket activity, as enthusiasm for new artificial intelligence initiatives from major technology companies outweighs concerns about ongoing U.S.-Iran tensions and elevated energy prices.US stock futures were also higher, with S&P 500 Index futures up 0.2%, Dow Jones Industrial Average futures advancing 0.3%, and Nasdaq futures gaining 0.2% before the start of regular trading.S&P Global manufacturing data for May will be released at 9:45 am ET, followed by the construction spending data for April, and the ISM's manufacturing reading for May at 10:00 am ET.In premarket action, bitcoin was down by 1.9%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2% lower, Ether ETF (EETH) retreated by 1.5%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 1.7%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.3% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was flat. The iShares US Consumer Staples ETF (IYK) retreated by 0.9%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.6%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) advanced by 0.4%.Taylor Morrison Home (TMHC) shares were up more than 22% pre-bell after the company agreed to be acquired by Berkshire Hathaway (BRK.A, BRK.B) for $6.8 billion in cash and a total equity value of $8.5 billionWinners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.1%, the Vanguard Health Care Index Fund (VHT) was down 0.03%, while the iShares US Healthcare ETF (IYH) was flat. The iShares Biotechnology ETF (IBB) gained by 0.03%.Grail's (GRAL) stock was down more than 17% premarket after the company reported its NHS-Galleri trial missed its primary endpoint of reducing combined Stage III and IV cancer diagnoses.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated by 0.5%. Direxion Daily Financial Bull 3X Shares (FAS) was down 1.5%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.4% lower.Coinbase Global (COIN) stock was down more than 3% before market open. Chief Legal Officer Paul Grewal sold 1,960 company shares for $346,683 on May 27, a regulatory filing with the US Securities and Exchange Commission showed.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated by 0.4%, while the Vanguard Industrials Index Fund (VIS) was down 0.5% and the iShares US Industrials ETF (IYJ) lost by 0.6%Diana Shipping (DSX) stock was down more than 0.4% before the opening bell after the company said Sunday it has issued an open letter urging Genco Shipping & Trading (GNK) investors to elect its six independent board candidates at the upcoming June 18 annual meeting. Genco stock was 0.8% lower.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 1.1%, and the iShares US Technology ETF (IYW) was 1.1% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 0.8%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 0.3% lower, while the iShares Semiconductor ETF (SOXX) declined by 0.7%.Dell Technologies (DELL) shares were up more than 1% in premarket activity a day after the company said it has launched its XPS 13 laptop.EnergyThe iShares US Energy ETF (IYE) was 0.1% higher, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.5%.Venture Global (VG) stock was up more than 1% before the opening bell after the company said its subsidiary Venture Global LNG plans to issue $2.25 billion in senior secured notes due 2034 and 2036.CommoditiesFront-month US West Texas Intermediate crude oil gained by 2.3% to $89.40 per barrel on the New York Mercantile Exchange. Natural gas was down 2.3% to $3.21 per 1 million British Thermal Units. The United States Oil Fund (USO) rose by 1.8%, while the United States Natural Gas Fund (UNG) was 2.4% lower.Gold futures for July retreated by 1.2% to $4,537.70 an ounce on the Comex. Silver futures increased by 0.3% to $76.10 an ounce. SPDR Gold Shares (GLD) was down by 1%, and the iShares Silver Trust (SLV) gained 0.4%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$BRK.A$BRK.B$COIN$DELL$DSX$EEM$EETH$EXI$FAS$FAZ$GLD$GRAL$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$PMR$QQQ$RTH$SLV$SOXX$SPY$TMHC$UNG$USO$VDC$VG$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Insider Trading

Grail Insider Sold Shares Worth $2,286,526, According to a Recent SEC Filing

Aaron Freidin, Chief Financial Officer, on April 08, 2026, sold 45,806 shares in Grail (GRAL) for $2,286,526. Following the Form 4 filing with the SEC, Freidin has control over a total of 260,669 common shares of the company, with 260,669 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1699031/000162828026024551/xslF345X05/wk-form4_1775775505.xml

$GRAL
Insider Trading

Grail Insider Sold Shares Worth $6,164,923, According to a Recent SEC Filing

Robert P Ragusa, Director, Chief Executive Officer, on April 08, 2026, sold 123,502 shares in Grail (GRAL) for $6,164,923. Following the Form 4 filing with the SEC, Ragusa has control over a total of 518,582 common shares of the company, with 518,582 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1699031/000162828026024550/xslF345X05/wk-form4_1775775497.xml

$GRAL
Insider Trading

Grail Insider Sold Shares Worth $3,078,169, According to a Recent SEC Filing

Joshua J. Ofman, Director, President, on April 08, 2026, sold 61,665 shares in Grail (GRAL) for $3,078,169. Following the Form 4 filing with the SEC, Ofman has control over a total of 371,216 common shares of the company, with 371,216 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1699031/000162828026024549/xslF345X05/wk-form4_1775775489.xml

$GRAL

Track with the FINWIRES app suite